BIAF
bioAffinity Technologies, Inc.Company Information
- Company Name
- bioAffinity Technologies, Inc.
- CIK
- CIK0001712762
- Category
- <br>Emerging growth company
- Ticker: Exchange
- BIAF: Nasdaq, BIAFW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 8731
- SIC Description
- Services-Commercial Physical & Biological Research
- Ticker
- BIAF
SEC filing data through
Insider Sentiment
- Last purchase
- 2022-09-01
- Last sale
- —
- Shares purchased (TTM)
- 92,341
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 761,578
- Shares outstanding
- 5,226,753
- Ownership
- 14.57%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- -36.34%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 2 | 3 | 6 | 8 | 1 | 0 | 1 | 1 | 1 | 2 | 3 | 5 | ||||||
| Accounts And Other Receivables Net Current | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 4 | 4 | 8 | 9 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 6 | ||||||
| Inventory Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finance Lease Right Of Use Asset | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Goodwill | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Intangible Assets Net Excluding Goodwill | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 8 | 8 | 11 | 12 | 5 | 6 | 7 | 7 | 7 | 8 | 8 | 10 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | ||||||
| Accrued Liabilities Current | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Deferred Revenue Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Notes Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finance Lease Liability Noncurrent | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Long Term Notes Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Liabilities | 4 | 4 | 4 | 3 | 7 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 4 | 4 | 7 | 9 | -2 | 1 | 3 | 3 | 3 | 5 | 5 | 7 | ||||||
| Additional Paid In Capital | 79 | 76 | 76 | 74 | 58 | 58 | 56 | 54 | 52 | 52 | 49 | 49 | ||||||
| Retained Earnings Accumulated Deficit | -76 | -72 | -69 | -65 | -60 | -56 | -54 | -51 | -49 | -47 | -45 | -42 | ||||||
| Liabilities And Stockholders Equity | 8 | 8 | 11 | 12 | 5 | 6 | 7 | 7 | 7 | 8 | 8 | 10 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | - | 20 | 20 | 20 | 20 | - | 20 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 350 | 350 | 100 | 100 | 350 | 100 | 25 | 25 | 100 | 25 | ||||||
| Common Stock Shares Issued | 7 | 4 | 4 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 7 | 4 | 4 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialbioAffinity Technologies, Inc. (BIAF) — SEC Financial Statements & Analysis
bioAffinity Technologies, Inc. (BIAF) is a services-commercial physical & biological research company, incorporated in DE. bioAffinity Technologies, Inc. trades on Nasdaq as: BIAF, BIAFW. bioAffinity Technologies, Inc. (BIAF)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, bioAffinity Technologies, Inc. carries a market cap of $63.66M, a P/E ratio of -4.19x, a P/B ratio of 16.89x, a P/S ratio of 10.79x, an enterprise value of $61.87M, and an EV/EBITDA multiple of -5.17x. On profitability, it posts a gross margin of 99.45%, an operating margin of -209.82%, a net margin of -257.33%, a Return on Equity (ROE) of -1860.15%, a Return on Assets (ROA) of -245.51%, and a Return on Invested Capital (ROIC) of -671.78%. Per share, it reports EPS of $-2.91, diluted EPS of $-2.91, free cash flow per share of $-2.21, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -23.17% year-over-year, net income growth of 29.91% year-over-year, and EPS growth of -80.10% year-over-year. On the balance sheet, it maintains a current ratio of 1.44x, a quick ratio of 1.24x, working capital of $1.18M, a debt-to-equity ratio of 1.02x, a debt ratio of 0.51, an interest coverage ratio of -276.15x, free cash flow of $-11.57M (TTM), and net debt of $-1.80M. Figures sourced from SEC EDGAR.
- Market Cap
- $63.66M
- P/E TTM
- -4.19x
- EPS TTM
- $-2.91
- P/B TTM
- 16.89x
- ROE TTM
- -1860.15%
- ROA TTM
- -245.51%
- Debt To Equity
- 1.02x
- Free Cash Flow TTM
- $-11.57M
- Net Revenue TTM Growth 1Y
- -23.17%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is bioAffinity Technologies, Inc. in?
bioAffinity Technologies, Inc. (BIAF) operates in the Services-Commercial Physical & Biological Research industry.
What exchange does BIAF trade on?
bioAffinity Technologies, Inc. (BIAF) trades on the Nasdaq.
Where is bioAffinity Technologies, Inc. incorporated?
bioAffinity Technologies, Inc. is incorporated in DE.
When was bioAffinity Technologies, Inc. (BIAF)'s most recent SEC filing?
bioAffinity Technologies, Inc. (BIAF)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is BIAF's market cap?
bioAffinity Technologies, Inc. (BIAF) has a market capitalization of $63.66M as of 2026-06-30.
What is BIAF's EPS (earnings per share)?
bioAffinity Technologies, Inc. (BIAF)'s trailing twelve month EPS is $-2.91 as of 2026-06-30.
What is BIAF's ROE (return on equity)?
bioAffinity Technologies, Inc. (BIAF)'s trailing twelve month Return on Equity (ROE) is -1860.15% as of 2026-06-30.
What is BIAF's ROA (return on assets)?
bioAffinity Technologies, Inc. (BIAF)'s trailing twelve month Return on Assets (ROA) is -245.51% as of 2026-06-30.
What is BIAF's ROIC (return on invested capital)?
bioAffinity Technologies, Inc. (BIAF)'s trailing twelve month Return on Invested Capital (ROIC) is -671.78% as of 2026-03-31.
What is BIAF's EV/EBITDA?
bioAffinity Technologies, Inc. (BIAF)'s trailing twelve month EV/EBITDA is -5.17x as of 2026-06-30.